then developed to remove the exposed photocresist, which leaves the exposed areas susceptible to chemical chrome etch. The etch removes the unprotected chrome. The rest of the photocresist is then removed, by either ultraviolet organic solvent or overdevelopment. The remaining chrome pattern is quickly oxidized by atmospheric exposure (typically within 30 seconds).

The ready chrome mask is now applied to the tissue slide and aligned manually, or using automatic software and pre-designed alignment marks. The slide plate sandwich is then exposed to UV to destroy the DNA of the unwanted cells. The slide and plate are separated and the slide is processed in a standard way to prepare for polymerase chain reaction (PCR) and potential identification of cancer sequences.

This work was done by Lawrence A. Wade of Caltech and Emil Kartalov, Darryl Shibata, and Clive Taylor of the University of Southern California for NASA’s Jet Propulsion Laboratory. Further information is contained in a TSP (see page 1).

Method for Impeding Degradation of Porous Silicon Structures
This method tailors degradation of a drug delivery system to enable controlled release of therapeutic agents.

Lyndon B. Johnson Space Center, Houston, Texas

This invention relates to surface modification of porosified silicon (pSi) structures with poly(alkylene) glycols for the purpose of controlled degradation of the silicon matrix and tailored release of encapsulated substances for biomedical applications. The pSi structures are currently used in diverse biomedical applications including bio-molecular screening, optical bio-sensing, and drug delivery by means of injectable/orally administered carriers and implantable devices.

The size of the pores and the surface chemistry of the pSi structure can be controlled during the microfabrication process and thereafter. A fine regulation of the degradation kinetics of mesoporous silicon structures is of fundamental importance. Polyethylene glycols (PEGs) represent the major category of surface modifying agents used in classical drug delivery systems and in pharmaceutical dosage forms. PEGylation enables avoidance of RES uptake, thus prolonging circulation time of intravenously injectable nanoveectors. PEG molecules demonstrate little toxicity and immunogenicity, and are cleared from the body through the urine (molecular weight, MW<30 kDa) or in the feces (MW>30kDa).

The invention focuses on the possibility of finely tuning the degradation kinetics of the pSi nanovectors and other structures through surface conjugation of PEGs with various backbone lengths/MWs. To prove the concept, pSi nanovectors were covalently conjugated to seven PEGs with MW from 245 to 5,000 Da and their degradation kinetics in physiologically relevant media (phosphate buffer saline, PBS pH7.4, and fetal bovine serum) was assessed by the elemental analysis of the Si using inductive coupled plasma atomic emission spectroscopy (ICP-AES). The conjugation of the PEG with lowest MW to the nanovector surface did not induce any change in the degradation kinetics in serum, but inhibited degradation and consequently the release of orthosilicic acid into buffer. When PEGs with the longer chains were evaluated, Si mass loss from the nanovector surface was slowed down, and the PEGylated structures were almost fully degraded within 18–24 hours in serum and within 48 hours in PBS. The most dramatic effect was observed for high MW PEGs 3,400 and 5,000 Da, which prominently inhibited the degradation of the systems, with complete degradation achieved only after four days. For these PEGs, during the early stages of the degradation, there was a “lag” period of little or no Si mass loss from the nanovector.

The obtained profiles were in agreement with the erosion of the nanovector surface as observed by scanning electron microscopy.

This work was done by Biana Godin Vlenticouk and Mauro Ferrari of the University of Texas Health Science Center at Houston, Biomedical Engineering, for Johnson Space Center.

In accordance with Public Law 96-517, the contractor has elected to retain title to this invention. Inquiries concerning rights for its commercial use should be addressed to:

University of Texas
Health Science Center at Houston
The Office of Technology Management
UCT 720
Houston, TX 77030
Phone No.: (713) 500-3369
E-mail: uthsch-otm@uth.tmc.edu
Refer to MSC-24566-1, volume and number of this NASA Tech Briefs issue, and the page number.

External Cooling Coupled to Reduced Extremity Pressure Device
The use of reduced-pressure boots and gloves may mitigate the effects of stroke and heart attacks.

Lyndon B. Johnson Space Center, Houston, Texas

Although suited astronauts are currently cooled with a Liquid Cooled Ventilation Garment (LCVG), which can remove up to 85 percent of body heat, their effectiveness is limited because cooling must penetrate layers of skin, muscle, fat, bone, and tissue to reach the bloodstream, where its effect is prominent. Vasoconstriction further reduces the effectiveness by limiting arterial flow when exposed to cold (the frostbite response), resulting in a time constant on